SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

NIO, Inc. operates as a holding company, which engages in the design, development, manufacture, and sale of smart electric vehicles. It offers its products under the brands NIO, ONVO, and FIREFLY. The company was founded by Bin Li and Li Hong Qin on November 28, 2014 and is headquartered in Shanghai, China.

NIO Inc - ADR

NIO Inc

NIO is trending as the community debates the impact of recent delivery updates, with bulls focusing on strong year-over-year growth and the rollout of new models like the ONVO L80, while bears highlight persistent concerns over stock dilution and market manipulation. Investors are closely monitoring price action as they look for a breakout from current levels, though discussions remain divided between those accumulating shares for long-term potential and those frustrated by consistent price suppression.

Rivian Automotive, Inc. engages in the design, development, and manufacture of category-defining electric vehicles and accessories. It operates through following segments: Automotive, Software and Services. The company was founded by Robert J. Scaringe in June 2009 and is headquartered in Irvine, CA.

Rivian Automotive Inc - Ordinary Shares - Class A

Rivian Automotive Inc

Rivian is facing heightened investor scrutiny ahead of its earnings report, with community sentiment divided between concerns over dilution and cash burn versus long-term optimism driven by the R2 platform rollout and production scaling. Investors are closely monitoring management's commentary on production milestones and capital management strategies, as they weigh near-term volatility against the company's ambitious growth targets.

Roblox Corp. engages in the provision of online gaming services. Its platform consists of Roblox Client, Roblox Studio, and Roblox Cloud. Roblox Client is an application that allows users to explore 3D digital worlds. Roblox Studio is the toolset that allows developers and creators to build, publish, and operate 3D experiences and other content accessed with Roblox Client. Roblox Cloud includes the services and infrastructure that power the human co-experience platforms. The company was founded by Erik Cassel and David B. Baszucki in March 2004 and is headquartered in San Mateo, CA.

Roblox Corporation - Ordinary Shares - Class A

Roblox Corp.

Roblox is facing significant downward pressure following weak engagement and bookings guidance, with market sentiment further soured by ongoing concerns regarding child safety and regulatory scrutiny. While some investors argue that the stock's current valuation is an attractive entry point for long-term growth, others remain skeptical due to persistent net losses and the platform's struggle to balance user safety with expansion.

Akanda Corp. is a cannabis cultivation, manufacturing, and distribution company, which engages in the provision of premium quality and ethically sourced medical cannabis products to patients. The company cultivates and processes natural cannabis at facilities in the Kingdom of Lesotho, Africa and intend to supply medicinal-grade cannabis biomass, cannabis flower, and cannabis concentrates to wholesalers. It also imports and sells medical cannabis-based products. The company was founded on July 16, 2021 and is headquartered in New Romney, the United Kingdom.

Akanda Corp

Akanda Corp is experiencing a massive, sentiment-driven rally fueled by an exceptionally low float and extreme short interest, leading to intense speculation about a potential gamma squeeze. While retail investors are actively sharing parabolic price targets and comparing the volatility to previous short-squeeze phenomena, market participants are also closely watching the company's recent pivot toward telecommunications infrastructure as a potential long-term catalyst.

Zebec's integrated products - real time payroll apps, on-chain payments infrastructure and networked DePIN - serve companies of all sizes, merchants and individuals and help transcend the boundaries of traditional banking and diminish the role of financial intermediaries.

Zebec Network

Zebec Network is capturing community attention as investors debate its long-term potential ahead of the upcoming XRP Vegas conference, with many speculating that a major partnership announcement will serve as a key catalyst. While some holders are expressing frustration over price volatility and questioning the project's transparency, a strong base of long-term supporters remains focused on the network's payroll infrastructure and upcoming ecosystem integrations as primary drivers for future growth.

Dogelon Mars

Dogelon Mars continues to trend due to persistent community efforts to drive social engagement and high-frequency trading chatter despite significant historical volatility. Investors are actively discussing the potential for long-term growth driven by speculative hype, meme culture, and hopes for major exchange listings.

Senseonics Holdings, Inc. is a medical technology company, which engages in the development and manufacture of glucose monitoring products. Its primary product is the brand Eversense CGM (continuous glucose monitoring) including sensors, smart transmitters, and mobile applications. The company was founded on June 26, 2014 and is headquartered in Germantown, MD.

Senseonics Holdings Inc

Senseonics is facing significant downward pressure following an $80 million stock and warrant offering, fueling intense community debate over dilution and leadership's capital management. Investors are actively scrutinizing the company's reliance on secondary offerings and potential reverse split risks, while many express deep frustration with management's performance despite the underlying technology's potential.

NVIDIA Corp. engages in the design and manufacture of computer graphics processors, chipsets, and related multimedia software. It operates through the following segments: Graphics Processing Unit (GPU) and Compute & Networking. The Graphics segment includes GeForce GPUs for gaming and PCs, the GeForce NOW game streaming service and related infrastructure, Quadro and NVIDIA RTX GPUs for enterprise workstation graphics, virtual GPU, or vGPU, software for cloud-based visual and virtual computing, automotive platforms for infotainment systems, and Omniverse Enterprise software for building and operating metaverse and 3D internet applications. The Compute & Networking segment consists of Data Center accelerated computing platforms and end-to-end networking platforms including Quantum for InfiniBand and Spectrum for Ethernet, NVIDIA DRIVE automated-driving platform and automotive development agreements, Jetson robotics and other embedded platforms, NVIDIA AI Enterprise and other software, and DGX Cloud software and services. The company was founded by Jen Hsun Huang, Chris A. Malachowsky, and Curtis R. Priem in April 1993 and is headquartered in Santa Clara, CA.

NVIDIA Corp

Nvidia is experiencing heightened volatility and selling pressure as investors rotate capital into other tech leaders, despite strong long-term projections for AI-driven data center demand. The community is actively debating whether this pullback represents a temporary consolidation and a buying opportunity or a structural shift driven by concerns over hyperscaler competition and high valuation expectations.

Cue Biopharma, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of immunotherapies to treat cancer and autoimmune diseases. Its products include CUE-400 series (autoimmune diseases), CUE-500 series (targeted cell depletion), and CUE-100 series (Oncology). The company was founded by Ronald D. Seidel III, Steven Almo, and Rodolfo Chaparro on December 31, 2014 and is headquartered in Boston, MA.

Cue Biopharma Inc

Cue Biopharma is currently experiencing significant market volatility driven by a mix of positive development milestones and investor apprehension surrounding a potential reverse stock split. The community is actively debating the company's recent preclinical success and partnership payments versus long-term concerns regarding cash runway, leadership transitions, and dilution.

United States Antimony Corp. engages in the extraction, processing and sale of antimony, zeolite, silver, and gold products. It operates through the following segments: United States Antimony Operations, Mexican Antimony Operations, Precious Metals Recovery, and United States Zeolite Operations. The company was founded by John C. Lawrence in June 1968 and is headquartered in Dallas, TX.

United States Antimony Corp.

United States Antimony Corp. is trending as investors monitor supply chain tensions following China's critical mineral export controls and the company's role as a domestic producer for defense-related industries. The community is actively debating the stock's volatility and its potential as a strategic play, with heavy discussion surrounding the upcoming earnings report and the impact of institutional accumulation.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Erasca (NASDAQ:ERAS) Trading 8.8% Higher - What's Next?

Erasca (NASDAQ:ERAS) Trading Up 8.8% - Time to Buy...

Erasca stock sinks almost 50% after patient death in cancer drug trial

A 66-year-old man developed severe lung inflammation about a month after starting ERAS-0015 and later died after withdrawing supportive care...

Erasca (NASDAQ:ERAS) Sees Large Volume Increase on Analyst Upgrade

Erasca (NASDAQ:ERAS) Sees Strong Trading Volume After Analyst Upgrade...

Dow Gains 150 Points; Coca-Cola Posts Upbeat Earnings

US stocks mixed with Dow up 150 pts. Dow up 0.27%, NASDAQ down 1.06%, S&P 500 down 0.52%. Energy shares up 1.7%. Coca-Cola beats earnings & raises guidance. Baiya Int'l up 126%, Nexera up 63...

Why Is Cancer Drug Developer Erasca Stock Plunging On Tuesday?

Erasca reports early ERAS-0015 data showing tumor response while rejecting Revolution Medicines' patent and trade secret allegations.read more...

<ul class="summary-bullets"><li>The death followed Grade 3 pneumonitis in a 66-year-old pancreatic cancer patient receiving a 24 mg dose.</li><li>ERAS-0015 showed strong early tumor response rates, including 62% in KRAS-mutant lung cancer.</li><li>Additional data from the Auroras-1 trial are expected in 2027, while results from its other candidate, ERAS-4001, are expected later this year.</li></ul>Shares of Erasca, Inc. (ERAS) plunged nearly 40% in extended trading on Monday after investors spotted a treatment-related death buried within safety disclosures, even as the company flagged strong early tumor response rates from a Phase 1 study of its experimental cancer therapy ERAS-0015.<a href="https://stocktwits.com/symbol/ERAS">ERAS stock</a> slid nearly 11% on Monday, logging its worst session in nearly eight months.&nbsp;<h2 class="st-heading-2">Treatment-Related Death Surfaces In ERAS Phase 1 Trial</h2>According to a fresh filing, one patient experienced Grade 3 pneumonitis that progressed to a treatment-related death. The patient was a 66-year-old male with metastatic pancreatic cancer receiving a 24 mg dose of ERAS-0015 who had pulmonary metastases and prior lung procedures before entering the study.&nbsp;The patient later discontinued treatment after developing pneumonitis one month after therapy initiation and later died following withdrawal of supportive care.<h2 class="st-heading-2">ERAS Cancer Trial Shows Strong Early Cancer Responses&nbsp;</h2>Alongside the safety update, Erasca reported strong early response signals from the company’s Auroras-1 study across KRAS-mutant cancers. In previously treated non-small cell lung cancer, ERAS-0015 showed a 62% tumor response rate at eight weeks, rising to 75% among patients who had already received immunotherapy and platinum chemotherapy. In pancreatic cancer, the therapy showed a 40% response rate at fourteen weeks, with most responding patients still on treatment at the time of analysis.The company also reported that all 14 evaluable patients showed large reductions in circulating tumor DNA levels. Based on these results, Erasca selected 24 mg and 32 mg once daily as the doses to move forward into expansion studies.&nbsp;Looking ahead, the company expects additional monotherapy expansion and combination dose-escalation data from the Auroras-1 study in the first half of 2027. Preliminary Phase 1 data for ERAS-4001, its pan-KRAS inhibitor program, is expected in the second half of this year.<h2 class="st-heading-2">RevMed Patent Claims Add Pressure&nbsp;</h2>Separately, Erasca disclosed in the new filing that it received a letter from the legal counsel for Revolution Medicines alleging that ERAS-0015 may infringe compositions claimed in a U.S. patent under the doctrine of equivalents. The letter also alleged possible trade-secret misappropriation from a third-party patent relating to ERAS-0015 and challenged comparisons between ERAS-0015 and RMC-6236 made in public disclosures.RMC-6236 is a cancer drug being developed by Revolution Medicines to treat tumors driven by KRAS mutations. Unlike older targeted therapies that focus on a single mutation, it works across multiple KRAS mutation types, which are common in cancers such as lung and pancreatic cancer. It is still in early-stage clinical testing.Revolution Medicines requested that Erasca cease manufacturing, using or selling ERAS-0015 outside Hatch-Waxman safe-harbor protections and stop making “untrue comparative statements.” However, Erasca said it believes the allegations are without merit and intends to contest them vigorously.<h2 class="st-heading-2">How Do Retail Traders Feel About ERAS?</h2>On Stocktwits, retail sentiment for ERAS slipped to ‘bearish’&nbsp; from ‘neutral’ levels from a day ago amid ‘extremely high’ message volume.<figure class="image"><img src="https://news.stocktwits-cdn.com/eras_ss_png_c88c88c3a3.webp" alt="eras ss.png" width="980" height="152"><figcaption>ERAS sentiment and message volume as of April 28 | Source: Stocktwits</figcaption></figure>One user&nbsp;<a href="https://stocktwits.com/docsamiles/message/651583972">said</a>, “Long-term effert on stock price depends on Erasca's relationship with FDA and whether a clinical hold is issued. Honesty and timeliness is paramount in FDA interactions.”<stembedurl>https://stocktwits.com/docsamiles/message/651583972</stembedurl>Another user&nbsp;<a href="https://stocktwits.com/FDAvalid/message/651581652">said</a>, “The Reality Check: If a drug makes a patient "decide" to stop all care, the toxicity is the problem, not the patient. You aren't buying a dip; you're buying a bio-hazard.”<stembedurl>https://stocktwits.com/FDAvalid/message/651581652</stembedurl>ERAS stock has surged nearly 1,300% over the past year.&nbsp;For updates and corrections, email newsroom[at]stocktwits[dot]com.Read Next:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/lucid-stock-crash-retail-eye-saudi-pif-buyout/cZB8j0uRe5d">Lucid Stock Is Crashing Hard And Leaves Retail Wondering If Saudi PIF Buyout Is A Good Exit Strategy</a>

In this photo illustration, the Erasca logo is seen displayed on a smartphone screen. (Photo Illustration by Thomas Fuller/SOPA Images/LightRocket via Getty Images)

ERAS Stock Slumps Nearly 40% After-Hours: Fine Print In 'Positive' Cancer Trial Reveals Treatment-Related Death 

ERAS Stock - Meanwhile, Revolution Medicines has alleged potential patent infringement and trade-secret issues related to ERAS-0015.

Equity

Meanwhile, Revolution Medicines has alleged potential patent infringement and trade-secret issues related to ERAS-0015.

Erasca Shares Phase 1 ERAS-0015 Data: 62% NSCLC Response, ctDNA Clearance Signals

Erasca (NASDAQ:ERAS) presented a preliminary Phase 1 data update for ERAS-0015 (also referred to as ERAS-15), which management described as a pan-RAS molecular glue, highlighting early signals of...

Erasca (NASDAQ:ERAS) Shares Gap Down - What's Next?

Erasca (NASDAQ:ERAS) Shares Gap Down - What's Next...

Stifel Nicolaus Issues Positive Forecast for Erasca (NASDAQ:ERAS) Stock Price

Stifel Nicolaus upped their price target on shares of Erasca from $20.00 to $30.00 and gave the company a "buy" rating in a report on Monday...

Erasca (NASDAQ:ERAS) Stock Price Down 6.3%  - Time to Sell?

Erasca (NASDAQ:ERAS) Shares Down 6.3% - Time to Sell...

Erasca, Inc. is a clinical stage precision oncology company. It focuses on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. It has assembled a wholly owned or controlled RAS/MAPK pathway focused pipeline comprising modality-agnostic programs. The company was founded by Jonathan E. Lim and Kevan Shokat on July 2, 2018 and is headquartered in San Diego, CA.

Current Price	$10.65
Prev Close	$9.11
Open	$9.14
Dividend Yield	0.00%
50-Day Moving Average	$15.73
Beta	1.36
Avg. Volume	5.63M
PE Ratio	-24.24

52-Week High	$24.28
52-Week Low	$1.06
Market Capitalization	$2.83B
EPS (Annual)	-$0.4393
Price to Book	9.31
Revenue Per Employee	$0.00

ERAS
Erasca Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest ERAS News

ERASErasca Inc